A pooled efficacy analysis of cerivastatin in the treatment of primary hyperlipidaemia

Clinical Drug Investigation

Volumn 18, Issue 6, 1999, Pages 433-444

  Stein, Evan ^a   Schopen, Ulrike ^b   Catagay, M ^b  

^a Pharmaceutical Product Development   (United States)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CERIVASTATIN; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DATA ANALYSIS; DIARRHEA; DIET; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; HEADACHE; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MYALGIA; NAUSEA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033369044     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199918060-00002     Document Type: Article

References (31)

1. 1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23
2. 2. Harris MI, Eastman RC, Cowie CC, et al. Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980-1985 World Health Organization diagnositic criteria. Diabetes Care 1997; 20 (12): 1859-62
3. 3. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19 Suppl. A: A12-9
4. 4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet 1994; 344; 1383-9
5. 5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335 (14): 1001-9
6. 6. The LIPID study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57
7. 7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group (WOSCOPS). N Engl J Med 1995; 333: 1301-7
8. 8. Buchwald H, Campos CT. Program on the surgical control of the hyperlipidemias: 1994 report. J Cardiovasc Pharmacol 1995; 25 Suppl. 4: S3-10
9. 9. Downs JR. Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27; 279 (20): 1615-22
10. 10. Assmann G, Schulte H, Cullen P. New and classical risk factors - the Munster Heart Study (PROCAM). Eur J Med Res 1997; 2 (6): 237-42
11. 11. Austin MA. Plasma triglycerides and coronary heart disease. Arterioscler Thromb Vasc Biol 1991; 11:2-14
12. 12. Miller M, Seidler A, Moalemi A, et al. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998 May; 31 (6): 1252-7
13. 13. Shear CL, Franklin FA, Stinnett S, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Circulation 1992; 85: 1293-303
14. 14. Dujovne C, Chremos A, Pool J, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: IV additional perspectives on the tolerability of lovastatin. Am J Med 1991; 191 Suppl. 1B: 25S-30S
15. 15. Bischoff H, Angerbauer R, Bender J, et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997; 135: 119-30
16. 16. Angerbauer R, Bishchoff H, Steinke W, et al. BAY w 6228. Hypolipidemic HMG-CoA reductase inhibitor. Drugs Future 1994; 19: 537-41
17. 17. Mück W, Ritter W, Dietrich H, et al. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 1997; 35: 261-4
18. 18. Mück W, Ritter W, Frey R, et al. Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 1997; 35: 250-4
19. 19. Lettieri J, Krol G, Mazzu AL, et al. Lack of phurmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis 1997; 130 Suppl.: S29-A109
20. 20. Schall R, Müller, FO, Hundt HKL, et al. No pharmacokinetic or pharmacodynamic interaction between cerivastatin and warfarin. J Clin Pharmacol 1995; 35: 306-13
21. 21. Mück W, Ochmann K, Unger S, et al. Influence of erythromycin pre-and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Clin Pharmacol Ther 1998; 53: 469-73
22. 22. Lettieri J, Krol G, Mazzu AL, et al. Effect of age and gender on the steady-state pharmacokinetics of cerivastatin [abstract no. PPDM 8159]. Pharm Res 1993; 10 Suppl.: S338
23. 23. Vormfelde S, Mück W, Freudenthaler S, et al. Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance. J Clin Pharmacol 1999; 39: 147-54
24. 24. Betteridge DJ, and the Cerivastatin Study Group. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. Int J Clin Pract 1999; 53 (4): 243-50
25. 25. Hanefeld M, Deslypere J-P, Ose L, et al. Efficacy and safety of 300 %g and 400 %g Cerivastatin once daily in patients with primary hypcrcholesterolaemia: a multicentre, randomized, double-blind placebo-controlled study. J Int Med Res 1999; 27: 115-29
26. 26. Ose L, Luurila O, Eriksson J, et al. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multi-national, randomised, double-blind study. Curr Med Res Opin 1999; 15 (3): 228-40
27. 27. Farnier M, and the Cerivastatin Study Group. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. Am J Cardiol 1998; 82: 47J-51J
28. 28. Myers GL, Cooper GR, Winn CL, et al. The Centers for Disease Control National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 1989; 9: 105-35
29. 29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
30. 30. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81 (4A): 66B-69B
31. 31. Stein E, Isaacsohn J, Stoltz R, et al. Pharmacodynamics, safety, tolerability and pharmacokinetics of the 0.8 mg dose of cerivastatin in patients with primary hypercholesterolemia. Am J Cardiol 1999; 83: 1433-6